$15.76
7.16% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US55910K1088
Symbol
DNTH
Sector
Industry

Magenta Therapeutics Inc Stock price

$16.97
-2.65 13.51% 1M
-10.49 38.20% 6M
-4.83 22.16% YTD
-9.26 35.30% 1Y
-32.31 65.56% 3Y
-81.91 82.84% 5Y
-215.35 92.70% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.89 4.98%
ISIN
US55910K1088
Symbol
DNTH
Sector
Industry

Key metrics

Market capitalization $545.16m
Enterprise Value $271.41m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 43.50
P/S ratio (TTM) P/S ratio 87.37
P/B ratio (TTM) P/B ratio 1.50
Revenue growth (TTM) Revenue growth 351.48%
Revenue (TTM) Revenue $6.24m
EBIT (operating result TTM) EBIT $-101.86m
Free Cash Flow (TTM) Free Cash Flow $-78.29m
Cash position $275.24m
EPS (TTM) EPS $-2.60
P/E forward negative
P/S forward 155.10
EV/Sales forward 77.21
Short interest 23.59%
Show more

Is Magenta Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Magenta Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Magenta Therapeutics Inc forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Magenta Therapeutics Inc forecast:

Buy
100%

Financial data from Magenta Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6.24 6.24
352% 352%
100%
- Direct Costs 0.41 0.41
69% 69%
7%
5.82 5.82
11,540% 11,540%
93%
- Selling and Administrative Expenses 24 24
4% 4%
387%
- Research and Development Expense 83 83
251% 251%
1,332%
-101 -101
116% 116%
-1,626%
- Depreciation and Amortization 0.41 0.41
69% 69%
7%
EBIT (Operating Income) EBIT -102 -102
111% 111%
-1,632%
Net Profit -85 -85
47% 47%
-1,362%

In millions USD.

Don't miss a Thing! We will send you all news about Magenta Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Magenta Therapeutics Inc Stock News

Neutral
GlobeNewsWire
24 days ago
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 milli...
Neutral
GlobeNewsWire
about one month ago
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion
Neutral
GlobeNewsWire
about one month ago
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:

Company Profile

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marino Garcia
Employees 78
Founded 2015
Website dianthustx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today